{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T19:45:03Z","timestamp":1768074303494,"version":"3.49.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"vor","delay-in-days":21,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.jacl.2025.08.011","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T16:50:12Z","timestamp":1755622212000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Simulation model to estimate pretreatment (baseline) low-density lipoprotein cholesterol levels in people living with homozygous familial hypercholesterolemia"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5735-8482","authenticated-orcid":false,"given":"Jing","family":"Gu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Koumas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandeep","family":"Tripathi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harshit","family":"Dixit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Amer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9417-6370","authenticated-orcid":false,"given":"Laurence","family":"Sperling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6432-1730","authenticated-orcid":false,"given":"Christie M.","family":"Ballantyne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"25","key":"10.1016\/j.jacl.2025.08.011_bib0001","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1093\/eurheartj\/ehad197","article-title":"2023 update on European Atherosclerosis Society consensus statement on homozygous familial hypercholesterolaemia: new treatments and clinical guidance","volume":"44","author":"Cuchel","year":"2023","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.jacl.2025.08.011_bib0002","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.029175","article-title":"Contemporary homozygous familial hypercholesterolemia in the United States: insights from the CASCADE FH registry","volume":"12","author":"Cuchel","year":"2023","journal-title":"J Am Heart Assoc"},{"issue":"7","key":"10.1016\/j.jacl.2025.08.011_bib0003","doi-asserted-by":"crossref","first-page":"665","DOI":"10.5551\/jat.RV17050","article-title":"Homozygous familial hypercholesterolemia","volume":"28","author":"Nohara","year":"2021","journal-title":"J Atheroscler Thromb"},{"issue":"22","key":"10.1016\/j.jacl.2025.08.011_bib0004","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1161\/CIR.0000000000000297","article-title":"The agenda for familial hypercholesterolemia: a scientific statement from the American Heart Association","volume":"132","author":"Gidding","year":"2015","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.jacl.2025.08.011_bib0005","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"issue":"24","key":"10.1016\/j.jacl.2025.08.011_bib0006","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.jacl.2025.08.011_bib0007","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jacl.2024.11.004","article-title":"High burden of disease in patients with homozygous familial hypercholesterolemia despite recent advances in therapies and updated guidelines: a real-world study","volume":"19","author":"Gu","year":"2025","journal-title":"J Clin Lipidol"},{"issue":"12","key":"10.1016\/j.jacl.2025.08.011_bib0008","doi-asserted-by":"crossref","DOI":"10.1161\/ATV.0000000000000177","article-title":"Lipoprotein apheresis: utility, outcomes, and implementation in clinical practice: a scientific statement from the American Heart Association","volume":"44","author":"Gianos","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"7","key":"10.1016\/j.jacl.2025.08.011_bib0009","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1007\/s11606-019-05620-4","article-title":"Recognition and treatment of homozygous familial hypercholesterolemia by primary care physicians: a survey from the National Lipid Association","volume":"35","author":"Hemphill","year":"2020","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.jacl.2025.08.011_bib0010","unstructured":"German C. Homozygous familial hypercholesterolemia: diagnosis and emerging therapies. 2022 Available at: https:\/\/www.acc.org\/latest-in-cardiology\/articles\/2022\/02\/18\/18\/04\/homozygous-familial-hypercholesterolemia. Accessed January 15, 2025."},{"issue":"1","key":"10.1016\/j.jacl.2025.08.011_bib0011","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s11883-024-01269-5","article-title":"Homozygous familial hypercholesterolemia treatment: new developments","volume":"27","author":"Blom","year":"2025","journal-title":"Curr Atheroscler Rep"},{"issue":"9","key":"10.1016\/j.jacl.2025.08.011_bib0012","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1001\/jamacardio.2017.2289","article-title":"Simulation of lipid-lowering therapy intensification in a population with atherosclerotic cardiovascular disease","volume":"2","author":"Cannon","year":"2017","journal-title":"JAMA Cardiol"},{"issue":"8","key":"10.1016\/j.jacl.2025.08.011_bib0013","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.amjcard.2019.01.028","article-title":"Simulation of the impact of statin intolerance on the need for ezetimibe and\/or proprotein convertase subtilisin\/kexin type 9 inhibitor for meeting low-density lipoprotein cholesterol goals in a population with atherosclerotic cardiovascular disease","volume":"123","author":"Cannon","year":"2019","journal-title":"Am J Cardiol"},{"issue":"6","key":"10.1016\/j.jacl.2025.08.011_bib0014","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.jacl.2022.10.001","article-title":"Simulation of lipid-lowering therapy (LLT) intensification in very high-risk patients with atherosclerotic cardiovascular disease","volume":"16","author":"Gu","year":"2022","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2025.08.011_bib0015","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ahj.2019.06.005","article-title":"Simulation of impact on cardiovascular events due to lipid-lowering therapy intensification in a population with atherosclerotic cardiovascular disease","volume":"216","author":"Cannon","year":"2019","journal-title":"Am Heart J"},{"issue":"2","key":"10.1016\/j.jacl.2025.08.011_bib0016","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jacc.2020.05.027","article-title":"Efficacy and safety of alirocumab in adults with homozygous familial hypercholesterolemia: the ODYSSEY HoFH trial","volume":"76","author":"Blom","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"21","key":"10.1016\/j.jacl.2025.08.011_bib0017","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1161\/01.CIR.0000018744.58460.62","article-title":"Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia","volume":"105","author":"Gagne","year":"2002","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.jacl.2025.08.011_bib0018","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.amjcard.2008.06.049","article-title":"Long-term safety and efficacy of low-density lipoprotein apheresis in childhood for homozygous familial hypercholesterolemia","volume":"102","author":"Hudgins","year":"2008","journal-title":"Am J Cardiol"},{"issue":"9965","key":"10.1016\/j.jacl.2025.08.011_bib0019","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","article-title":"Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2025.08.011_bib0020","unstructured":"Viatris. LIPITOR\u00ae (atorvastatin calcium) prescribing information. 2022 Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/020702Orig1s079correctedlbl.pdf Accessed January 15, 2025."}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287425003757?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287425003757?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T04:47:49Z","timestamp":1758602869000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287425003757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":20,"alternative-id":["S1933287425003757"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2025.08.011","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Simulation model to estimate pretreatment (baseline) low-density lipoprotein cholesterol levels in people living with homozygous familial hypercholesterolemia","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2025.08.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of National Lipid Association.","name":"copyright","label":"Copyright"}]}}